The role of omentectomy during the surgical staging of uterine serous carcinoma

2003 ◽  
Vol 13 (2) ◽  
pp. 212-215 ◽  
Author(s):  
P. A. Gehrig ◽  
L. Van Le ◽  
W. C. Fowler
Keyword(s):  
Ovarian Cancer ◽  
Surgical Procedures ◽  
Surgical Staging ◽  
Serous Carcinoma ◽  
Exact Test ◽  
Uterine Serous Carcinoma ◽  
Stage Ivb ◽  
Sensitivity Specificity ◽  
Omental Metastasis

Uterine serous carcinoma (USC) has a propensity for extrauterine spread, and some suggest that this disease be staged as an ovarian cancer, and thus include omental sampling. However, given the primary organ involved, the staging recommendations do not include omental sampling. The aim of this study is to evaluate the role of omental sampling during the surgical staging of USC. We retrospectively identified cases of USC at our institution from January 1990 to June 2000 and abstracted surgical procedures, stage, and sites of metastasis. Fisher's exact test was used to calculate sensitivity, specificity, and positive and negative predictive value. We identified 65 women with USC, of which 52 underwent omental evaluation. Thirty four of the omentums were visually normal and benign on histologic review. Two were visually negative and histologically positive for metastatic serous carcinoma. The remaining 16 specimens were grossly involved with histologic confirmation of disease. The sensitivity of a visually negative omentum is 0.89 (P < 0.0001). Microscopic omental metastasis from USC is rare. When the omentum is involved, thereby upstaging the patient to stage IVB disease, the disease is generally diagnosed by gross visualization. We conclude that omental sampling does not need to be included in the routine surgical staging of USC.

Impact of pleural effusion in ovarian cancer: A retrospective study in Lleida, Spain.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e17534-e17534
Author(s):  
Eleonor Paola Murata ◽  
Silvia Bielsa ◽  
Marina Pardina ◽  
Antonieta Salud Salvia ◽  
Laura Porcel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Retrospective Study ◽  
Pleural Effusion ◽  
Median Overall Survival ◽  
Serous Carcinoma ◽  
Stage Iiic ◽  
Disease Evolution ◽  
Medical Reports ◽  
Stage Ivb

e17534 Background: The presence of pleural effusion in the evolution of patients with ovarian cancer is not uncommon. In one series of 123 patients, malignant pleural effusion at the diagnoses was observed in 29%, and 70% during the course of the disease. Methods: This observational, retrospective study included patients with ovarian cancer and pleural effusion between July 2007 and December 2019 in Lleida, province of Catalonia, Spain. Data were collected from electronic medical reports. This study analyzed the clinical features of ovarian cancer patients with pleural effusion and its impact on their survival. Results: Data from 189 patients with ovarian cancer were collected. The median age was 63 years old. Pleural effusion was observed in 81 patients, 55 at the diagnosis and 26 in the disease evolution. Fifty five percent were confirmed as malignant etiology. Most of the patients were diagnosed with an advanced stage (38.3% stage IIIC, 12.3% stage IVA, 40.7% stage IVB), and 74.1% were high-grade serous carcinoma. When the pleural effusion was observed at the diagnosis, the median overall survival was 20.8 vs 69.3 months in the absence of it (p < 0.001). When the pleural effusion was observed at any time of the disease, the median overall survival was 26.7 vs 90.4 months without it (p < 0.001). Conclusions: In this study, patients with ovarian cancer and pleural effusion, at diagnosis or in the course of the disease, experienced reduced survival compared with the absence of it.

The role of appendectomy in surgical procedures for ovarian cancer

1992 ◽  
Vol 46 (1) ◽  
pp. 42-44 ◽  
Author(s):  
R. Fontanelli ◽  
D. Paladini ◽  
F. Raspagliesi ◽  
E. di Re
Keyword(s):  
Ovarian Cancer ◽  
Surgical Procedures

The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy

2014 ◽  
Vol 132 (2) ◽  
pp. 312-315 ◽  
Author(s):  
Mauro Signorelli ◽  
Robert Fruscio ◽  
Lorenzo Ceppi ◽  
Tiziana Dell'Anna ◽  
Domenico Vitobello ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Surgical Staging ◽  
Second Look ◽  
Early Stage Ovarian Cancer

Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center

2021 ◽  
Author(s):  
Antonino Ditto ◽  
Umberto Leone Roberti Maggiore ◽  
Salvatore Lopez ◽  
Fabio Martinelli ◽  
Giorgio Bogani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Oncologic Outcomes ◽  
Serous Carcinoma ◽  
Tertiary Center ◽  
Uterine Serous Carcinoma

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma

2014 ◽  
Vol 24 (Supp 3) ◽  
pp. S83-S89 ◽  
Author(s):  
Satoru Sagae ◽  
Nobuyuki Susumu ◽  
Akila N. Viswanathan ◽  
Daisuke Aoki ◽  
Floor J. Backes ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Gynecologic Cancer ◽  
Survival Rates ◽  
Serous Carcinoma ◽  
Molecular Characteristics ◽  
Histologic Subtype ◽  
High Propensity ◽  
Stage Disease ◽  
Uterine Serous Carcinoma

ObjectivesUterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.MethodsAs one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.ResultsBoth USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum- and taxane-based chemotherapy should be considered in the treatment of both early- and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive.ConclusionsUterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.

scholarly journals Incidence of omental metastasis in uterine serous carcinoma: study protocol for a systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e043141
Author(s):  
Cui Hu ◽  
Lin-Lin Zhang ◽  
Yu Cheng ◽  
Fei-Xue Xue ◽  
Ya Jia ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Gynecologic Oncology ◽  
Serous Carcinoma ◽  
Published Data ◽  
Wide Range ◽  
Uterine Serous Carcinoma ◽  
Endometrial Cancers ◽  
Omental Metastasis

IntroductionUterine serous carcinoma accounts for only about 10% of all endometrial cancers but this subtype is the most common amongst non-endometrioid endometrium cancers and contributes to more than half of recurrence and deaths attributed to endometrial cancers. A more extensive surgical staging and adjuvant therapies for uterine serous carcinoma are recommended by many guidelines. However, guidelines vary on recommendations for the methods that should be used for omentum assessment in uterine serous carcinoma and the previously reported incidence of omental metastasis in uterine serous carcinoma had a wide range because of the heterogeneity among these studies. As far as we know, there are no systematic review and meta-analysis available on this topic. The aim of our proposed study is to statistically synthesise the data examining the incidence of omental metastasis in uterine serous carcinoma.Methods and analysisSystematic searches of three databases (PubMed, Embase and Web of Science) will be performed using prespecified search strategies. We will include original studies that reported incidence of omental metastasis in uterine serous carcinoma and are published before 30 August 2020. Our different investigators will independently conduct the eligible study selection, assess the quality of included studies and extract the needed data. If appropriate, the relevant data will be pooled through a random-effect or fixed-effect meta-analysis based on the heterogeneity among included studies. We will evaluate the overall quality of evidence using appropriate methods.Ethics and disseminationThis proposed study will be based on published data, and thus, there is no requirement for ethics approval. We aim to publish the results of this study in a peer-reviewed journal with good visibility for the fields of gynaecology and gynecologic oncology.PROSPERO registration numberCRD42020200891.

Sign in / Sign up

Export Citation Format

Share Document